Cas:55405-68-0 3,6-Dibromopyrazolo[1,5-a]pyrimidine manufacturer & supplier

Chemical Name:3,6-Dibromopyrazolo[1,5-a]pyrimidine

CAS.NO:55405-68-0

Synonyms:3,6-dibromo-pyrazolo[1,5-a]pyrimidine;3,6-Dibromopyrazol<1,5-a>pyrimidin

Molecular Formula:C₆H₃Br₂N₃

Molecular Weight:276.91600

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:2.36g/cm3

Index of Refraction:1.802

PSA:30.19000

Exact Mass:274.86900

LogP:2.25430

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3,6-dibromo-pyrazolo[1,5-a]pyrimidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,pyrimidin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,5-a&gt Use and application,pyrimidin technical grade,usp/ep/jp grade.

Related News: After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply. 3,6-Dibromopyrazolo[1,5-a]pyrimidine manufacturer The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented. 3,6-Dibromopyrazolo[1,5-a]pyrimidine supplier The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented. 3,6-Dibromopyrazolo[1,5-a]pyrimidine vendor This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved. 3,6-Dibromopyrazolo[1,5-a]pyrimidine factory Government prosecutors often consider whether a corporation made a genuine effort to investigate and address potentially illegal activities once learning of them.